Blogs & Insights
Explore the latest in biotech and research, crafted to inspire your next breakthrough.
New Updates
ALK7 Obesity Target: What Roche's $1.16B Rona RNAi Deal Means for Fat-Focused Drug Discovery
View Details
More Opsin, or a Different Target? The Delivery Question Behind This Year's Optogenetics Nobel
View Details
Bispecific ADCs: Solving Antigen Heterogeneity or Masking Payload Resistance?
View Details
Dual-Target siRNA: the Future of RNAi Therapeutics
View Details
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Filter By
All Topics
Animal Science and Quality
Autoimmunity & Inflammation
Cardiovascular Research
Cell & Gene Therapy
Genetic Disorders and Genomics
HUGO-Ab
Immunology
Infectious Diseases & Vaccines
Metabolism & Obesity
Neuroscience
Oncology
Ophthalmology
Precision Medicine & Biomarkers
Rare Diseases
Regenerative Biology
Milestones & Highlights
Filter By
Metabolism & Obesity
ALK7 Obesity Target: What Roche's $1.16B Rona RNAi Deal Means for Fat-Focused Drug Discovery
View Details
Ophthalmology
More Opsin, or a Different Target? The Delivery Question Behind This Year's Optogenetics Nobel
View Details
HUGO-Ab
Bispecific ADCs: Solving Antigen Heterogeneity or Masking Payload Resistance?
View Details
Metabolism & Obesity
Dual-Target siRNA: the Future of RNAi Therapeutics
View Details
Neuroscience
How to Choose the Right Alzheimer's Disease Research Model
View Details
Animal Science and Quality
Three Novartis Clinical Setbacks in Eight Days: What CAR-T, Pelacarsen, and Del-Desiran Reveal About Translational Risk
View Details
HUGO-Ab
Beyond Topo I: Why Genentech’s $1B Deal with DualityBio Signals the Next Phase of ADC Development
View Details
Metabolism & Obesity
Is INHBE Only Half of the Activin Story?
View Details
Oncology
Enhertu’s First-Line Phase III Win in HER2-Mutant NSCLC: Are ADCs Moving into Precision Frontline Therapy?
View Details
1
2
3
4
5
6
...
21
22
More